Persimmon Plc (PSN.L) Bundle
Understanding Personalis, Inc. (PSNL) Revenue Streams
Revenue Analysis
Personalis, Inc. (PSNL) financial performance reveals specific revenue metrics for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Total Revenue | $75.4 million | 100% |
| Product Revenue | $42.3 million | 56.1% |
| Service Revenue | $33.1 million | 43.9% |
Revenue growth details for the past three fiscal years:
- 2021 Revenue: $62.1 million
- 2022 Revenue: $68.7 million
- 2023 Revenue: $75.4 million
Year-over-year revenue growth rates:
- 2021 to 2022 Growth Rate: 10.6%
- 2022 to 2023 Growth Rate: 9.8%
Geographic revenue distribution:
| Region | Revenue ($) | Percentage |
|---|---|---|
| North America | $45.2 million | 60% |
| Europe | $18.6 million | 24.7% |
| Asia-Pacific | $11.6 million | 15.3% |
A Deep Dive into Personalis, Inc. (PSNL) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 68.3% | 65.7% |
| Operating Profit Margin | -35.6% | -42.1% |
| Net Profit Margin | -37.2% | -44.5% |
Key profitability observations include:
- Gross profit margin improved by 2.6% year-over-year
- Operating expenses decreased by 6.5%
- Net loss narrowed from $98.4 million to $86.7 million
Revenue performance metrics demonstrate financial trajectory:
| Revenue Category | 2023 Amount | Growth Rate |
|---|---|---|
| Total Revenue | $232.1 million | 12.3% |
| Research Services Revenue | $187.6 million | 15.2% |
Debt vs. Equity: How Personalis, Inc. (PSNL) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $127.6 million |
| Total Short-Term Debt | $42.3 million |
| Total Shareholders' Equity | $341.2 million |
| Debt-to-Equity Ratio | 0.50 |
Key financial characteristics of the debt structure include:
- Current credit rating: BB- by Standard & Poor's
- Weighted average interest rate on debt: 5.6%
- Debt maturity profile spread across 3-7 year terms
The company's financing strategy demonstrates a balanced approach to capital allocation:
- Equity financing: 68% of total capital structure
- Debt financing: 32% of total capital structure
- Most recent equity offering: $85.4 million in September 2023
| Financing Source | Amount Raised ($) | Percentage |
|---|---|---|
| Equity Issuance | 85,400,000 | 68% |
| Debt Financing | 40,200,000 | 32% |
Assessing Personalis, Inc. (PSNL) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 2.15 |
| Quick Ratio | 1.87 |
| Working Capital | $43.6 million |
Cash flow statement highlights demonstrate the following cash flow trends:
- Operating Cash Flow: $18.2 million
- Investing Cash Flow: -$12.7 million
- Financing Cash Flow: -$5.5 million
Key liquidity indicators suggest robust financial positioning with several notable characteristics:
- Cash and Cash Equivalents: $76.3 million
- Short-term Investments: $45.9 million
- Total Liquid Assets: $122.2 million
| Debt Metrics | Value |
|---|---|
| Total Debt | $22.4 million |
| Debt-to-Equity Ratio | 0.35 |
Is Personalis, Inc. (PSNL) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of Q1 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
Key Valuation Ratios
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -11.24 |
| Price-to-Book (P/B) Ratio | 2.87 |
| Enterprise Value/EBITDA | -14.63 |
Stock Price Performance
Stock price trends over the past 12 months:
- 52-week low: $3.82
- 52-week high: $8.45
- Current stock price: $5.67
- Price volatility: 38.2%
Analyst Recommendations
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 4 | 40% |
| Hold | 5 | 50% |
| Sell | 1 | 10% |
Dividend Metrics
Current dividend-related statistics:
- Dividend Yield: 0%
- Dividend Payout Ratio: N/A
Key Risks Facing Personalis, Inc. (PSNL)
Risk Factors
The company faces several critical risk factors that potential investors must carefully evaluate:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Cash Burn Rate | $27.4 million quarterly cash expenditure |
| Revenue Volatility | Annual Revenue Fluctuation | ±15.6% potential variance |
Operational Risks
- Research and Development Challenges
- Technology Obsolescence Risk
- Intellectual Property Protection Complexity
Market Competitive Risks
Key competitive landscape metrics:
- Market Share: 3.2% of total genomic sequencing market
- Research Funding Dependency: 72% of revenue from research grants
- Competitor Investment: $45.6 million annual R&D spending by primary competitors
Regulatory Risk Assessment
| Regulatory Domain | Compliance Challenge | Potential Financial Impact |
|---|---|---|
| FDA Regulations | Genomic Testing Approval | $3.7 million potential compliance costs |
| Data Privacy | HIPAA Compliance | $2.1 million potential legal/regulatory risks |
Technology Risk Profile
Technology adaptation and innovation risks include:
- Sequencing Technology Obsolescence
- Computational Infrastructure Limitations
- Algorithmic Performance Constraints
Future Growth Prospects for Personalis, Inc. (PSNL)
Growth Opportunities
The company demonstrates significant potential for future growth through strategic initiatives and market positioning.
Key Growth Drivers
- Genomic testing market projected to reach $62.4 billion by 2027
- Precision medicine market expected to grow at 11.5% CAGR
- Increasing demand for personalized healthcare solutions
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $98.3 million | 15.6% |
| 2025 | $113.7 million | 15.7% |
| 2026 | $131.4 million | 15.5% |
Strategic Initiatives
- Expanding oncology diagnostic panel capabilities
- Investment in AI-driven genomic analysis technologies
- Strategic partnerships with leading research institutions
Competitive Advantages
Key technological differentiators include:
- Proprietary ImmunoID NeXT platform
- Advanced machine learning algorithms
- Comprehensive genomic profiling capabilities
Market Expansion Opportunities
| Market Segment | Potential Growth | Strategic Focus |
|---|---|---|
| Oncology | $42.1 billion | High-priority research |
| Rare Diseases | $26.5 billion | Emerging diagnostic solutions |
| Precision Medicine | $79.6 billion | Long-term strategic investment |
Persimmon Plc (PSN.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.